Medpace Holdings (NASDAQ: MEDP) is one of 196 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it compare to its peers? We will compare Medpace Holdings to similar companies based on the strength of its analyst recommendations, dividends, valuation, institutional ownership, earnings, profitability and risk.
Risk and Volatility
Medpace Holdings has a beta of -0.86, suggesting that its share price is 186% less volatile than the S&P 500. Comparatively, Medpace Holdings’ peers have a beta of 1.63, suggesting that their average share price is 63% more volatile than the S&P 500.
Valuation & Earnings
This table compares Medpace Holdings and its peers revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Medpace Holdings||$378.52 million||$110.08 million||60.84|
|Medpace Holdings Competitors||$207.83 million||-$2.34 million||0.16|
Medpace Holdings has higher revenue and earnings than its peers. Medpace Holdings is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Insider & Institutional Ownership
16.0% of Medpace Holdings shares are held by institutional investors. Comparatively, 47.0% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 25.8% of Medpace Holdings shares are held by insiders. Comparatively, 13.8% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This table compares Medpace Holdings and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Medpace Holdings Competitors||-3,986.19%||-109.18%||-43.29%|
This is a summary of recent recommendations for Medpace Holdings and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Medpace Holdings Competitors||468||2232||6126||117||2.66|
Medpace Holdings currently has a consensus price target of $33.25, indicating a potential downside of 2.41%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 0.58%. Given Medpace Holdings’ peers stronger consensus rating and higher possible upside, analysts clearly believe Medpace Holdings has less favorable growth aspects than its peers.
Medpace Holdings beats its peers on 7 of the 13 factors compared.
Medpace Holdings Company Profile
Medpace Holdings, Inc. is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
Receive News & Ratings for Medpace Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.